Profund Advisors LLC grew its stake in shares of Eli Lilly And Co (NYSE:LLY) by 8.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 29,972 shares of the company’s stock after purchasing an additional 2,301 shares during the quarter. Profund Advisors LLC’s holdings in Eli Lilly And Co were worth $3,939,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in LLY. Pacitti Group Inc. bought a new position in shares of Eli Lilly And Co in the 4th quarter worth about $25,000. Sugarloaf Wealth Management LLC bought a new stake in Eli Lilly And Co in the 4th quarter valued at about $26,000. Solstein Capital LLC bought a new stake in Eli Lilly And Co in the 4th quarter valued at about $34,000. Capital Wealth Alliance LLC bought a new stake in Eli Lilly And Co in the 4th quarter valued at about $34,000. Finally, Retirement Network bought a new stake in Eli Lilly And Co in the 4th quarter valued at about $38,000. 77.83% of the stock is owned by institutional investors.
Shares of LLY stock traded up $12.41 during trading on Thursday, hitting $134.35. 6,723,618 shares of the company were exchanged, compared to its average volume of 4,786,929. The company has a debt-to-equity ratio of 5.30, a quick ratio of 0.89 and a current ratio of 1.16. The firm has a market capitalization of $117.61 billion, a price-to-earnings ratio of 15.34, a P/E/G ratio of 1.54 and a beta of 0.34. The business’s 50-day simple moving average is $137.27 and its 200 day simple moving average is $124.78. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $147.87.
Several analysts recently weighed in on LLY shares. Mizuho started coverage on shares of Eli Lilly And Co in a research report on Wednesday, February 5th. They issued a “neutral” rating and a $148.00 price objective on the stock. Barclays started coverage on shares of Eli Lilly And Co in a research note on Thursday, February 27th. They set an “overweight” rating on the stock. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Cantor Fitzgerald reissued a “buy” rating and set a $156.00 target price on shares of Eli Lilly And Co in a research note on Tuesday, February 18th. Finally, Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $116.00 to $150.00 in a research note on Wednesday, December 18th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Eli Lilly And Co currently has an average rating of “Buy” and a consensus target price of $142.18.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $146.61, for a total value of $29,322,000.00. Following the completion of the sale, the insider now directly owns 113,589,351 shares in the company, valued at $16,653,334,750.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Myles O’neill sold 25,000 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total transaction of $3,503,750.00. Following the completion of the sale, the senior vice president now owns 44,773 shares of the company’s stock, valued at $6,274,935.95. The disclosure for this sale can be found here. Insiders sold 682,645 shares of company stock valued at $95,516,671 over the last quarter. Corporate insiders own 0.11% of the company’s stock.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Net Asset Value
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.